Τίτλος:
Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Genetic defects of monoamine neurotransmitters are rare neurological diseases amenable to treatment with variable response. They are major causes of early parkinsonism and other spectrum of movement disorders including dopa-responsive dystonia. Objectives: The objective of this study was to conduct proteomic studies in cerebrospinal fluid (CSF) samples of patients with monoamine defects to detect biomarkers involved in pathophysiology, clinical phenotypes, and treatment response. Methods: A total of 90 patients from diverse centers of the International Working Group on Neurotransmitter Related Disorders were included in the study (37 untreated before CSF collection, 48 treated and 5 unknown at the collection time). Clinical and molecular metadata were related to the protein abundances in the CSF. Results: Concentrations of 4 proteins were significantly altered, detected by mass spectrometry, and confirmed by immunoassays. First, decreased levels of apolipoprotein D were found in severe cases of aromatic L-amino acid decarboxylase deficiency. Second, low levels of apolipoprotein H were observed in patients with the severe phenotype of tyrosine hydroxylase deficiency, whereas increased concentrations of oligodendrocyte myelin glycoprotein were found in the same subset of patients with tyrosine hydroxylase deficiency. Third, decreased levels of collagen6A3 were observed in treated patients with tetrahydrobiopterin deficiency. Conclusion: This study with the largest cohort of patients with monoamine defects studied so far reports the proteomic characterization of CSF and identifies 4 novel biomarkers that bring new insights into the consequences of early dopaminergic deprivation in the developing brain. They open new possibilities to understand their role in the pathophysiology of these disorders, and they may serve as potential predictors of disease severity and therapies. © 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society
Συγγραφείς:
Tristán-Noguero, A.
Borràs, E.
Molero-Luis, M.
Wassenberg, T.
Peters, T.
Verbeek, M.M.
Willemsen, M.
Opladen, T.
Jeltsch, K.
Pons, R.
Thony, B.
Horvath, G.
Yapici, Z.
Friedman, J.
Hyland, K.
Agosta, G.E.
López-Laso, E.
Artuch, R.
Sabidó, E.
García-Cazorla, À.
Περιοδικό:
Movement Disorders
Εκδότης:
John Wiley and Sons Inc
Λέξεις-κλειδιά:
5 hydroxytryptophan; 6 pyruvoyltetrahydropterin synthase; apolipoprotein D; aromatic levo amino acid decarboxylase; beta2 glycoprotein 1; biological marker; carbidopa; collagen type 6; collagen type 6 A3; dihydropteridine reductase; dopamine receptor stimulating agent; dopamine transporter; guanosine triphosphate cyclohydrolase I; levodopa; monoamine oxidase inhibitor; oligodendrocyte myelin glycoprotein; protein; sepiapterin reductase; tetrahydrobiopterin; tyrosine 3 monooxygenase; unclassified drug; biological marker, adolescent; adult; Article; cerebrospinal fluid analysis; child; cohort analysis; controlled study; data analysis software; disease association; disease severity; female; human; human tissue; immunoassay; major clinical study; male; mass spectrometry; metabolic disorder; monoamine metabolism; preschool child; priority journal; protein cerebrospinal fluid level; proteomics; school child; young adult; disorders of amino acid and protein metabolism; dystonic disorder; proteomics; severity of illness index, Amino Acid Metabolism, Inborn Errors; Biomarkers; Dystonic Disorders; Humans; Proteomics; Severity of Illness Index
